Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability

Dacomitinib (DMB) is a second-generation irreversible tyrosine kinase inhibitor (TKI) that is claimed to overcome the disadvantages of the resistance reported for first-line epidermal growth factor receptor (EGFR) TKIs. Towards the end of 2018, the US Food and Drug Administration approved DMB in the...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:PLoS One
Autori principali: Abdelhameed, Ali S., Kadi, Adnan A., Attwa, Mohamed W., AlRabiah, Haitham
Natura: Artigo
Lingua:Inglês
Pubblicazione: Public Library of Science 2019
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6448865/
https://ncbi.nlm.nih.gov/pubmed/30947315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0214598
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi